Upload
phungdung
View
239
Download
0
Embed Size (px)
Citation preview
Intracellular Cytokine Staining Resource Guide
� Toll Free 1.877.BIOLEGEND (�46.5343)
Intracellular Cytokine Staining Resource Guide
Table of Contents
Intracellular Cytokine Staining: Protein Transport Inhibitors and Kinetics of Production for Optimal Detection 3
Cytokine/Chemokine Intracellular Staining Guide 9
Intracellular Cytokine Staining Protocol 12
Product Listing 14
All BioLegend products are for Research Use Only, unless otherwise specified. Not intended for diagnostic or therapeutic use. They are not for resale without prior written authorization.Alexa Fluor® is a registered trademark of Molecular Probes, Inc. Alexa Fluor® dye antibody conjugates are sold under license from Molecular Probes, Inc. for research use only, except for use in combination with microarrays and high content screening, and are covered by pending and issued patents.Allophycocyanin (APC) conjugates: US Patent No. 5,714,386Cy™, including Cy5, Cy5.5, Cy7, is a trademark of Amersham Biosciences Ltd.Cyanine (Cy) dyes: US Patent Nos. 4,981,977; 5,268,486 and other patents pending.BioLegend®, BioLegend Logo, and other trademarks are the trademarks and property of BioLegend, Inc. ©Copyright 2006 BioLegend, Inc.
Intracellular Cytokine Staining Resource GuideIntracellular Cytokine Staining Resource Guide
www,biolegend.com • [email protected] 3
Intracellular Cytokine StainingCytokines are protein mediators involved in immunoregula-tion of leukocyte responses and the development/progression of diseases including cancer, infectious disease, and autoim-munity. Several antibody-based strategies can be used to study cytokine production in bulk populations or at the single cell level including ELISAs, ELISPOTs, and intracellular cyto-kine staining. ELISAs and ELISPOTs are limited in that they detect only secreted cytokines in bulk populations, and, thus are restricted by the effective rates of production relative to adsorption, specific binding, internalization, and degradation of a given cytokine. Intracellular staining, on the other hand, allows assessment of individual cells within a population and does not rely on the detection of secreted cytokines. In addi-tion, this powerful technique can be used simultaneously with surface staining to permit identification and characteriza-tion of the individual cytokine- secreting cells.
Intracellular cytokine stain-ing and flow cytometric analy-sis was first demonstrated by Andersson et al.1 who showed that paraformaldehyde fixation, permeabilization with saponin, and cytokine-specific monoclo-nal antibodies could be used to detect cytokines inside various cells using fluorescent micros-copy and flow cytometry. More recent studies have documented the utility of this method for the identification of cytokines in discrete subpopulations of cells,2 the kinetic analysis of cytokine production,3 analysis using whole blood,4 and multi-parameter analysis to assess cytokine production in phenotypically/func-tionally distinct lymphocyte sub-populations.
Cytokine secretion in T lymphocytes has been shown to play a central role in immune regulation, susceptibility to disease,
and disease progression in autoimmunity, cancer, and a variety of infectious diseases. On the basis of cytokine production profiles, CD4+ T lymphocytes can be divided into distinct sub-sets (Table I). Understanding the divergence of differentiated CD4+ cytokine-producing subsets has dominated an entire field of immunology for over 15 years. T helper 1 (Th1) cells produce several characteristic type I cytokines, notably IL-2 and IFN-γ, that direct cell-mediated inflammatory reactions.5 When well developed, these responses allow the immune response to be most effective toward intracellular viral and bacterial pathogens. Th2 cells, on the other hand, produce a distinct set of cytokines that include IL-4, IL-5, IL-6, IL-10, and IL-13
resulting in enhanced B cell activation and antibody pro-duction.5 These so-called type II responses are most effective at promoting allergic responses and eliminating parasites. Th1- and Th2-type cytokines have been shown to be inhibitory for the differentiation and function of the reciprocal phenotype. Experimental studies have suggested, however, that these phenotypes may not be rigidly “fixed” and that conversion between the two functionally distinct phenotypes can occur under certain micro-environ-mental conditions.6
The imbalance of Th1/Th2 cytokine production has been shown to be associated with dis-ease pathogenesis. A dominant
Th1 response has been reported in sarcoidosis,7 tuberculosis,8 and collagen-induced arthritis,9 among other diseases. On the other hand, Th2 predominance is observed in asthma,10 atopic dermatitis,11 and a variety of neoplasias including basal cell carcinoma, and gastrointestinal cancer.12–14 In cancers, in particular, IL-2 and IFN-γ are often downregulated either systemically or locally (tumor infiltrating lymphocytes or in
Table IDistinct Patterns of Cytokine Pro-duction by Th0, Th1, and Th2 Cells
Th0* Th1 Th2
IL-2 IL-2 ●
IL-3 IL-3 ●
IL-4 ● IL-4
IL-5 ● IL-5
IL-6 ● IL-6
IL-10 ● IL-10
IL-13 ● IL-13
IFN-γ IFN-γ ●
TNF-α TNF-α ●
TNF-β TNF-β TNF-βGM-CSF GM-CSF GM-CSF
* Upon activation, naïve Th cells become Th0 cells with characteristics of both Th1 and Th2 cells. Further stimulation induces deviation of Th0 cells towards either a Th1 or Th2 cell based on the pattern
Intracellular Cytokine Staining Resource Guide
4 Toll Free 1.877.BIOLEGEND (�46.5343)
Intracellular Cytokine Staining Resource Guide
tumor-draining lymph nodes). Using multi-parameter flow cytometry, investigators have been able to address whether these differences were attributable to a reduced differentiation and accumulation of Th1 cells or whether the observed Th2 domi-nance reflected reduced Th1 cytokine production in individual cells. Experimental findings suggest that these differences are the result of decreased frequencies of CD4+ cells producing Th1-type cytokines.15 One goal of the numerous cancer vac-cine trials currently underway is to expand the Th1-like cell population favoring cell-mediated responses. Recent reports suggest that tetramer staining, measures for determining cel-lular proliferation, and intracellular cytokine staining can be combined to monitor peptide-specific responses,16, 17 suggest-ing that such strategies might be used as a surrogate marker for vaccine efficacy.
Measuring Intracellular Cytokines: Protein Transport Inhibitors
Several factors may affect intracellular cytokine detection including cell type, type of stimulation, time of stimulation, protein transport inhibitors used during cell culture, and the method of cell fixation and permeabilization. Unstimulated lymphocytes generally produce undetectable amounts of cyto-kine and require stimulation with agents such as antigen/pep-tide, agonist antibodies against the T cell receptor, or non-spe-cific activators such as phorbol myristate acetate (PMA) and ionomycin. Following activation, lymphocytes rapidly produce and secrete cytokines (as early as 2–4 hours). Kinetic analyses are warranted for each cytokine to be determined, as production of discrete cytokines may vary. In addition, it is important to use an inhibitor of protein transport when measuring the number of cells and the relative amount of cytokine produced in a given population. Two commonly used compounds employed to trap cytokines in the cell are brefeldin A and monensin.18, 19 Brefeldin A was isolated from the fungi Penicillium brefeldianum and inhibits protein secretion early in a pre-Golgi compartment (between the endoplasmic reticulum and the Golgi). Monensin was isolated from Streptomyces cinnamonensis and shown to be
a sodium ionophore that disrupts intracellular hydrogen and sodium gradients. Monensin differs from brefeldin A in that the effect of this fungal product appears to be on the final stages of secretory vesicle maturation in the Golgi.19 Although monensin appears to be more commonly used to block cytokine secre-tion, there are reported differences between brefeldin A and monensin with regard to intracellular cytokine measurement. For example, brefeldin A has been reported to yield higher cell viability compared to monensin in mouse splenocytes activated with antibodies against CD3/CD28 or PMA/ionomycin,20 and several reports have shown that specific cytokine expression could be altered depending on the protein transport inhibitor used.21, 22 Brefeldin A has been shown to trap a greater percent-age of TNF-α,21, 22 IL-6,21 and IL-1β inside cells compared to monensin.21, 22 A detailed protocol for intracellular cytokine staining can be found on page 12.
Measuring Intracellular Cytokines: Kinetics of Production
Additional parameters to be considered when measuring intracellular cytokines are the kinetics of production follow-ing various activation stimuli. Depending on the time after specific activation that the samples are harvested for analy-sis, differences in the magnitude of the response as well as the responding populations can be observed. Figure 1 shows human peripheral blood mononuclear cells activated with 12-O-tetradecanoylphorbol-13-acetate (TPA) for either 6 or 24 hrs. In both cases, PBMCs were treated with monensin prior to intracellular staining with the specific antibodies (X-axis) and anti-CD3 (Y-axis) as indicated. As is evident from the experimental data shown, TPA stimulation induces a robust production of IL-2, IFN-γ, and TNF-α in the T cell popula-tion in as little as 6 hours, whereas the induction of IL-10 and IL-4 are poor using these activation conditions. The overall percentage of IL-2 producing cells increased from 6 hrs to 24 hrs (27% to 44%, respectively) in the lymphocyte population, although the mean fluorescence intensity (MFI) of the IL-2 expressing population decreased (662 to 379, respectively).
Figure 1 ➡➤ Human PBMCs were stimulated with TPA for either 6 or 24 hrs before harvest. Monensin was included in the culture media for the entire incubation period. Cells were fixed, permeabilized and stained as described in the “Intracellular Cytokine Staining Protocol” found on page 12. The Y-axis shows staining with anti-human CD3 PE-Cy5 (Clone HIT3a, Cat No. 300309); the X-axis shows staining with various PE-conjugated anti-cytokine antibodies including: anti-human IL-2 (Clone MQ1-17H12, Cat. No. 500306), anti-human IL-4 (Clone MP4-25D2, Cat. No. 500808), anti-human IFN-γ (Clone 4S.B3, Cat. No. 501403), anti-human IL-10 (Clone JES3-9D7, Cat. No. 501403), and anti-human TNF-α (Clone MAb11, Cat. No. 502908).
Intracellular Cytokine Staining Resource GuideIntracellular Cytokine Staining Resource Guide
www,biolegend.com • [email protected] 5
Figure 1
CD3
100100
104
103
102
101
104103102101
IL-227%, MFI=662
CD3
100100
104
103
102
101
104103102101
IL-41%, MFI=79
CD3
100100
104
103
102
101
104103102101
IFN-γ15%, MFI=556
CD3
100100
104
103
102
101
104103102101
IL-10<1%
CD3
100100
104
103
102
101
104103102101
TNF-α36%, MFI=244
TPA-Stimulated PBMC (6 hrs)
100100
104
103
102
101
104103102101
Control
CD3
CD3
100100
104
103
102
101
104103102101
IL-244%, MFI=379
CD3
100100
104
103
102
101
104103102101
IL-41%, MFI=44
CD3
100100
104
103
102
101
104103102101
IFN-γ21%, MFI=484
CD3
100100
104
103
102
101
104103102101
IL-10<1%
CD3
100100
104
103
102
101
104103102101
TNF-α38%, MFI=159
TPA-Stimulated PBMC (24 hrs)
100100
104
103
102
101
104103102101
Control
CD3
Intracellular Cytokine Staining Resource Guide
6 Toll Free 1.877.BIOLEGEND (�46.5343)
Intracellular Cytokine Staining Resource Guide
Figure 2
CD14
100100
104
103
102
101
104103102101
IL-1α
CD14
100100
104
103
102
101
104103102101
IL-6
CD14
100100
104
103
102
101
104103102101
GM-CSF
CD14
100100
104
103
102
101
104103102101
TNF-α
LPS-Stimulated PBMC (6 hrs)
100100
104
103
102
101
104103102101
Control
CD14
CD14
100100
104
103
102
101
104103102101
IL-1αCD14high
CD14low
CD14
100100
104
103
102
101
104103102101
IL-6
CD14
100100
104
103
102
101
104103102101
GM-CSF
CD14
100100
104
103
102
101
104103102101
TNF-α
LPS-Stimulated PBMC (24 hrs)
100100
104
103
102
101
104103102101
Control
CD14
Intracellular Cytokine Staining Resource GuideIntracellular Cytokine Staining Resource Guide
www,biolegend.com • [email protected] 7
Similar, although less dramatic changes, were also observed in the T cell population staining for IFN-γ and TNF-α (see Figure 1). Even at 24 hrs, TPA-stimulated PBMCs produced little IL-10 or IL-4. Taken together, these data indicate that TPA-stimu-lated T cells produce an early Th1-like cytokine response and that while the proportion of T cells secreting these cytokines increases over time, the relative amount of cytokine produced per cell decreases with prolonged activation.
Figure 2 shows PBMCs stimulated with lipopolysaccharide (LPS) for either 6 or 24 hrs. In both cases, PBMCs were treated with monensin prior to intracellular staining with the specific cytokine antibodies (X-axis) and anti-CD14 (Y-axis) as indi-cated. The monocyte population was gated based on forward and side scatter. As is evident from the experimental data shown, LPS stimulation induces robust production of IL-1α, IL-6, TNF-α (characteristic of the classic “acute phase” inflam-matory response) in as little as 6 hours, whereas the induction of GM-CSF is relatively poor. At 24 hrs following stimulation, however, GM-CSF production is obvious in the CD14+ cell population. Interestingly, at 24 hrs there are two populations of CD14+ cytokine-producing cells present (CD14high and CD14low). The cell population with downregulated CD14 expression (CD14low) shows substantially decreased levels of IL-1α and IL-6 compared to the CD14high population. Taken together, these data indicate that LPS-stimulated monocytes produce an early (6 hr) inflammatory cytokine response characterized by IL-1α, TNF-α and IL-6 production. GM-CSF production by monocytes, on the other hand, is a more delayed response (seen at 24 hrs following LPS stimulation). Downregulation of CD14 expression on a portion of the LPS-stimulated monocyte popu-lation is obvious at 24 hrs and this CD14low population shows a concomitant decrease in IL-1α and, to a lesser extent, IL-6 production. Because the choice of protein transport blocker, activation condition, and stimulation period are critical param-eters for the accurate analysis of both intracellular cytokines and chemokines in a particular target population, it is essential to optimize experimental conditions. To assist the investiga-
tor in this endeavor, we have included a cytokine/chemokine staining guide for both mouse and human cells (please refer to pages 9–11).
Concluding remarks
The measurement of intracellular cytokines by flow cytometry is an important investigative tool that permits simultaneous cellular profiling of surface proteins and cytokine produc-tion. By combining phenotypic markers with intracellular cytokines, the investigator can gain important information about the responding population(s) and the type of immune response elicited (Th1, Th2, inflammatory). The investigator should carefully consider the type of protein transport inhibi-tor, the type of cellular activation, and the kinetics of activa-tion to obtain an accurate snapshot of cytokine production in a given cell population. BioLegend is proud to offer a wide array of proven antibodies for cytokine intracellular stain-ing and surface markers to distinguish responding cellular populations.23, 24 Please consult pages 14–15 for a current list of cytokine and chemokine antibodies and formats against mouse, rat, and human proteins.
References 1. Andersson, U., Hallden, G., Persson, U., Hed, J., Moller, G.,
and DeLey, M. 1988. Enumeration of IFN-gamma produc-ing cells by flow cytometry. Comparison with fluorescence microscopy. J. Immunol. Methods 112:139.
2. Jung, T., Schnauer, U., Heusser, C., Neumann, C., and Reiger, C. 1993. Detection of intracellular cytokines by flow cytom-etry. J. Immunol. Methods 159:197.
3. Mascher, B., Schlenke, P., and Seyfarth, M. 1999. Expression and kinetics of cytokines determined by intracellular staining using flow cytometry. J. Immunol. Methods 223:115.
4. Sewell, W.A.C., North, M.E., Webster, A.D.B., and Far-rant, J. 1997. Determination of intracellular cytokines by flow-cytometry following whole-blood culture. J. Immunol. Methods 209:67.
Figure 2Human PBMCs were stimulated with LPS for either 6 or 24 hrs before harvest. Monensin was included in the culture media for the entire incubation period. Cells were fixed, permeabilized and stained as described in the “Intracellular Cytokine Staining Protocol” found on page 12. The Y-axis shows staining with anti-human CD14 APC (Clone M5E2, Cat. No. 301807); the X-axis shows staining with various PE-conjugated anti-cytokine antibodies including: anti-human IL-1α (Clone 364-3B3-14, Cat. No. 500105), anti-human IL-6 (Clone MQ2-13A5, Cat. No. 501106), anti-human GM-CSF (Clone BVD2-21C11, Cat. No. 502305), and anti-human TNF-α (Clone MAb11, Cat. No. 502908).
Intracellular Cytokine Staining Resource Guide
8 Toll Free 1.877.BIOLEGEND (�46.5343)
Intracellular Cytokine Staining Resource Guide
5. Mosmann, T.R., and Coffman, R.L. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
6. Abbas, A.K., Murphy, K.M., and Sher, A. 1996. Functional diversity of helper T lymphocytes. Nature 383:787.
7. Baumer, I., Zissel, G., Schlaak, M., and Muller, Q.J. 1997. TH1/TH2 cell distribution in pulmonary sarcoidosis. Am. J. Respir. Cell Mol. Biol. 16:171.
8. Grange, J.M., Stanford, J.L., and Rook, G.A. 1995. Tubercu-losis and cancer: parallels in host responses and therapeutic approaches? Lancet 345:1350.
9. Mauri, C., Williams, R.O., Walmsley, M., and Feldmann, M. 1996. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur. J. Immunol. 26:1511.
10. Robinson, D.S., Hamid, Q., Ying, S., Tsicopoulos, A., Bar-kans, J., and Bentlry, A.M. 1992. Predominant TH2-like bron-choalveolar population in atopic asthma. N. Engl. J. Med. 326:298.
11. Nakazawa, M., Sugi, N., Kawaguchi, H., Ishii, N, Nakajima, H., and Minami, M. 1997. Predominance of type 2 cytokine producing CD4 (+) and CD8 (+) cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 99:673.
12. Yamamura, M., Modlin, R.L., Ohmen, J.D., and Moy, R.L. 1993. Local expression of anti-inflammatory cytokines in cancer. J. Clin. Invest. 91:1005.
13. Kim, J., Modlin, R.L., Moy, R.L., Dubinett S.M., McHugh, T., Nickoloff, B.J., and Uyemura, K. 1995. IL-10 production in cutaneous basal and squamous cell carcinoma. J. Immunol. 155:2240.
14. Pellegrini, P., Berghella, A.M., Del Beato, T., Cicia, S., Adorno, D., and Casciani, C.U. 1996. Disregulation of TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother. 42:1.
15. Nakayama, H., Kitayama, J., Muto, T., and Nagawa, H. 2000. Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. Jpn. J. Clin. Oncol. 30:301.
16. Tesfa, L., Volk, H. D., and Kern, F. 2003. A protocol for combin-ing proliferation, tetramer staining and intracellular cytokine detection for the flow-cytometric analysis of antigen specific T cells. J. Biol. Regul. Homeost. Agents 17:366.
17. Hobeika, A. C., Morse, M. A., Osada, T., Ghanayem, M., Neid-zwiecki, D., Barrie, R., Lyerly, H. K., and Clay, T. M. 2005. Emunerating antigen-specific T-cell responses in peripheral blood: A comparison of MHC tetramer, ELISPOT, and intra-cellular cytokine analysis. J. Immunother. 28:63.
18. Dinter, A., and Berger, E.G. 1998. Golgi-disturbing agents. Histochem. Cell Biol. 109:571.
19. Mollenhauer, H.H., Morre, D.J., and Rowe, L.D. 1990. Altera-tion of intracellular trafficby monensin: mechanism, speci-ficity, and relationship to toxicity. Biochim. Biophys. Acta 1031:225.
20. Nylander, S., and Kalies, I. 1999. Brefeldin A, but not monen-sin, completely blocks CD69 expression on mouse lympho-cytes: efficacy of inhibitors of protein secretion in protocols for intracellular staining by flow cytometry. J. Immunol. Methods 224:69.
21. Schuerwegh, A. J., Stevens, W. J., Bridts, C. H., Clerck, L. S. D. 2001. Evaluation of monensin and brefeldin A for flow determination of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha in monocytes. Cytometry 46:172.
22. O’NeIL-Anderson, N. J., and Lawrence, D.A. 2002. Differential modulation of surface and intracellular protein expression by T cells after stimulation in the presence of monensin or brefeldin A. Clin. Diag. Lab. Immunol. 9:243.
23. Kang, S. S., and Allen, P. M. 2005. Priming in the presence of IL-10 results in direct enhancement of CD8+ T cell primary responses and inhibition of secondary responses. J. Immunol. 174:5382.
24. Ko, S.-Y., Ko, H.-J., Chang, W.-S., Park, S.-H., Kweon, M.-N., Kang, C.-Y. 2005. α-Galactosylceramide can act as a nasal vac-cine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175:3309.
Intracellular Cytokine Staining Resource GuideIntracellular Cytokine Staining Resource Guide
www,biolegend.com • [email protected] �
Cytokine/Chemokine Intracellular Staining Guide
Cytokine/Chemokine Clone name Target Cells Stimulation
Stimulation period
Protein transport blocker
Surface Marker
MOUSE
IL-1α ALF-161Thioglycollate-elicited peritoneal macrophages
LPS (1 μg/ml) 4–6 hoursmonensin or brefeldin A
MAC-3
IL-2 JES6-5H4 SplenocytesPMA (20 ng/ml) plus ionomycin (1μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
IL-3 MP2-8F8
Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (2 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3–4 days
PMA (20 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD4*
IL-4 11B11
Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (2 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3–4 days
PMA (20 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD4*
IL-5 TRFK5
Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (2 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3–4 days
PMA (20 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD4*
IL-6 MP5-20F3Thioglycollate-elicited peritoneal macrophages
LPS (1 μg/ml) 4–6 hoursmonensin or brefeldin A
MAC-3
IL-10 JES5-16E3
Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (2 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3–4 days
PMA (20 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD4*
IL-12 C15.6Thioglycollate-elicited peritoneal macrophages
IFN-γ (10 ng/ml) prime for 2 hours, then add LPS (1 μg/ml)
18–24 hoursmonensin or brefeldin A
MAC-3
IL-17 TC11-18H10.1 EL-4 cellsPMA (20 ng/ml) plus ionomycin (1 μg/ml)
18–24 hoursmonensin or brefeldin A
Intracellular Cytokine Staining Resource Guide
10 Toll Free 1.877.BIOLEGEND (�46.5343)
Intracellular Cytokine Staining Resource Guide
Cytokine/Chemokine Clone name Target Cells Stimulation
Stimulation period
Protein transport blocker
Surface Marker
GM-CSF MP1-22E9
Splenocytes stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (2 μg/ml) for 2 days, wash and then culture in IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 3–4 days
PMA (20 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
IFN-γ XMG1.2 SplenocytesPMA (20 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
MCP-1 2H5Thioglycollate-elicited peritoneal macrophages
LPS (1 μg/ml) 18–24 hoursmonensin or brefeldin A
MAC-3
TNF-α MP6-XT22 SplenocytesPMA (20 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
HUMAN
IL-1α 364-3B3-14 PBMCs LPS (100 ng/ml) 4–6 hoursmonensin or brefeldin A
CD14#
IL-1β JK1B-1 PBMCs LPS (100 ng/ml) 4–6 hoursmonensin or brefeldin A
CD14#
IL-2 MQ1-17H12 PBMCsPMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
IL-3 BVD3-1F9
Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (5 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3–4 days
PMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD4*
IL-4MP4-25D2 or 8D4-8
PBMCsPMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD4*
IL-5 JES1-39D10
Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (5 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3–4 days
PMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin/brefeldin A
CD4*
IL-6 MQ2-13A5 PBMCs LPS (100 ng/ml) 4–6 hoursmonensin or brefeldin A
CD14#
Cytokine/Chemokine Intracellular Staining Guide (continued)
Intracellular Cytokine Staining Resource GuideIntracellular Cytokine Staining Resource Guide
www,biolegend.com • [email protected] 11
Cytokine/Chemokine Clone name Target Cells Stimulation
Stimulation period
Protein transport blocker
Surface Marker
IL-8 JK8-1 PBMCs LPS (100 ng/ml) 4–6 hoursmonensin or brefeldin A
CD14#
IL-9 MH9H4
Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (5 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3–4 days
PMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD4*
IL-10JES3-9D7 or JES3-19F1
PBMCs LPS (100 ng/ml) 18–24 hoursmonensin or brefeldin A
CD14#
IL-12 C11.5 PBMCs
IFN-γ (100 ng/ml) prime 2 hours, then plus LPS (100 ng/ml)
18–24 hoursmonensin or brefeldin A
CD14#
IL-13 JES10-5A2
Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (5 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3–4 days
PMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD4*
GM-CSF BVD2-21C11
PBMCs stimulated with soluble anti-CD3 (UCHT1, 1 μg/ml) + soluble anti-CD28 (5 μg/ml) for 2 days, wash and then culture in IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 3–4 days
PMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
IFN-γ 4S.B3 or B27 PBMCsPMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
MCP-15D3-F7 or 2H5
PBMCs LPS (100 ng/ml) 18–24 hoursmonensin or brefeldin A
CD14#
TNF-α MAB11 PBMCsPMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
TNF-β 359-81-11
PBMCs stimulated with soluble anti-CD3 (UCHT1, 1 μg/ml) + soluble anti-CD28 (5 μg/ml) for 2 days, wash and then culture in IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 3–4 days
PMA (50 ng/ml) plus ionomycin (1 μg/ml)
4–6 hoursmonensin or brefeldin A
CD3
Notes: * surface expression of CD4 is down-modulated by PMA and ionomycin stimulation. # surface staining of CD14 is down-regulated by LPS stimulation.
Cytokine/Chemokine Intracellular Staining Guide (continued)
Intracellular Cytokine Staining Resource Guide
1� Toll Free 1.877.BIOLEGEND (�46.5343)
Intracellular Cytokine Staining Resource Guide
Intracellular Cytokine Staining ProtocolApplication Notes:
1. Activated cell populations can be prepared from in vivo-stimulated tissues or from in vitro-stimulated cultures (e.g., antigen-specific activation or mitogen-induced). It is critical to include a protein transport inhibitor such as brefeldin A (Cat. No. 420601) or monensin (Cat. No. 420701) in the last 4–6 hours of cell culture activation. The cells can be suspended and distributed to 12 × 75 mm plastic tubes or microwell plates for immunofluorescent staining.
2. Different cytokines/chemokines have different produc-tion peaks. In order to obtain optimal staining signals, the stimulation conditions for each stimulant need to be optimized.
3. Some antibodies recognizing native cell surface mark-ers may not bind to fixed/denatured antigens. For this reason, it is recommended that staining of cell surface antigens be done with live, unfixed cells PRIOR to fixa-tion/permeabilization and staining of intracellular cyto-kines. Altering the procedure such that cells are fixed prior to staining of cell surface antigens requires that paraformaldehyde-denatured antigen-reactive antibody clones be empirically identified.
Fixation:
1. If staining intracellular antigens (e.g. IFN-γ or IL-4), first perform cell surface antigen staining as described in BioLegend’s Cell Surface Immunofluorescence Stain-ing Protocol (BioLegend website under “Support”), then fix cells in 0.5 ml/tube Fixation Buffer (Cat. No. 420801) in the dark for 20 minutes at room temperature.
2. Centrifuge at 350 × g for 5 minutes, discard supernatant.
3. To put the experiment “on hold” at this point for future staining and analysis, wash cells 1× with Cell Staining Buffer. Resuspend cells in Cell Staining Buffer and store cells at 4°C (short term) or in 90% FCS/10% DMSO for storage at -80°C (long term, for fixed cells without sur-face antigen staining). The frequencies of cytokine-pro-ducing cells present in activated human PBMC cultures
can vary widely due to donor variability. Therefore, cryopreserved cells from a single donor are useful for longitudinal studies.
Permeabilization:
4. Dilute 10X Permeabilization Wash Buffer (Cat. No. 421001) to 1X in DI water.
5. Resuspend fixed cells in Permeabilization Wash Buffer and centrifuge at 350 × g for 5–10 minutes.
6. Repeat step 5 twice.
Intracellular Staining:
7. Resuspend fixed/permeabilized cells in residual Per-meabilization Wash Buffer and add a predetermined optimum concentration of fluorochrome conjugated antibody of interest (e.g. anti-IFN-γ-PE) or an appropri-ate negative control for 20 minutes in the dark at room temperature.
8. Wash 2× with 2 ml of Permeabilization Wash Buffer and centrifuge at 350 × g for 5 minutes.
9. If primary intracellular antibody is biotinylated, it will be necessary to perform fluorochrome conjugated Strep-tavidin incubations and subsequent washes in Permea-bilization Wash Buffer.
10. Resuspend fixed and intracellularly labeled cells in 0.5 ml Cell Staining Buffer and analyze with appropriate controls.
Note: To confirm specific anti-cytokine staining, a blocking experiment is recommended in which cells are fixed/permeabilized then preincubated with an excess amount of unlabeled anti-cytokine antibody and/or the recombinant cytokine of interest is preincubated with fluorochrome-conjugated anti-cytokine antibody before its addition to the cells.
Activation and Intracellular Staining of Whole Blood:
1. Dilute heparinized whole blood 1:1 with sterile appro-priate tissue culture medium.
Intracellular Cytokine Staining Resource GuideIntracellular Cytokine Staining Resource Guide
www,biolegend.com • [email protected] 13
2. At this stage, in vitro cellular stimulation by either anti-gen or mitogen can be performed. If intending to stain intracellular antigens (e.g. IFN-γ or IL-4), addition of an efficient protein transport inhibitor such as brefeldin A (Cat. No. 420601) or monensin (Cat. No. 420701) is criti-cal. After addition of a suitable cellular activator, aliquot 200 µl of the whole blood cell suspension into 12 × 75 mm plastic tubes and incubate for 4–6 hours in 5% CO2 at 37°C.
3. Add 2 ml of 1X Red Blood Cell Lysis Buffer (Cat. No. 420301) and incubate for 5–10 minutes at room temperature.
4. Centrifuge at 350 × g for 5 minutes and discard the supernatant.
5. Wash cells 1X with Cell Staining Buffer and perform cell surface immunofluorescent staining.
6. Fix, permeabilize and stain intracellular antigens as described above.
Flow Cytometric Analysis:
Set PMT voltage and compensation using cell surface staining controls. Set quadrant markers based on blocking controls, isotype controls, or unstained cells. For proper flow cytometric analysis, cells stained by this method should be inspected by light microscopy and/or flow light scatter pattern to confirm that they are well dispersed. Bivariate dot plots or probability contour plots can be generated upon data analysis to display the frequencies of and patterns by which individual cells co-express certain levels of cell surface antigen and intracellular cytokine proteins.
Related Information:
1. Jung, T., Schauer, U., Heusser, C., Neumann, C., and Rieger, C. 1993. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods 159:197.
2. Vikingsson, A., Pederson, K., and Muller, D. 1994. Enu-meration of IFN-gamma producing lymphocytes by flow cytometry and correlation with quantitative measure-ment of IFN-gamma. J. Immunol. Methods 173:219.
3. Prussin, C., and Metcalfe, D.D. 1995. Detection of intra-cytoplasmic cytokine using flow cytometry and directly
conjugated anti-cytokine antibodies. J. Immunol. Meth-ods 188:117.
4. Elson, L.H., Nutmann, T.B., Metcalfe, D.D., and Prussin, C. 1995. Flow cytometric analysis for cytokine produc-tion identifies T helper 1, T helper 2, and T helper 0 cells within the human CD4+CD27- lymphocyte suppopula-tion. J. Immunol. 154:4294.
5. Assenmacher, M., Schmitz, J., and Radbruch, A. 1994. Flow cytometric determination of cytokines in activated murin T helper lymphocytes: expression of interleukin-10 in interferon-gamma and in interleukin-4-expressing cells. Eur. J. Immunol. 24:1097.
Reagent List:
1. Cell Staining Buffer (Cat. No. 420201)
2. Monensin (Cat. No. 420701)
3. RBC Lysis Buffer (Cat. No. 420301)
4. Brefeldin A (Cat. No. 420601)
5. Fixation Buffer (Cat. No. 420801)
6. Permeabilization Wash Buffer (Cat. No. 421001)
Intracellular Cytokine Staining Resource Guide
14 Toll Free 1.877.BIOLEGEND (�46.5343)
Intracellular Cytokine Staining Resource Guide
Specificity Clone Puri
fied
Bio
tin
FITC
PE APC
Ale
xa F
luor
® 48
8
Ale
xa F
luor
® 64
7
Ale
xa F
luor
® 70
0
Mouse
Mouse IL-1α ALF-161 X X
Mouse IL-2 JES6-5H4 X X X X X X X X
Mouse IL-3 MP2-8F8 X X
Mouse IL-4 11B11 X X X X X
Mouse IL-5 TRFK5 X X X
Mouse IL-6 MP5-20F3 X X
Mouse IL-10 JES5-16E3 X X X X X X X
Mouse IL-12/IL-23 p40 C15.6 X X X
Mouse IL-17 TC11-18H10.1 X X
Mouse GM-CSF MP1-22E9 X X X
Mouse IFN-γ XMG1.2 X X X X X X X X
Mouse MCP-1 2H5 X X
Mouse TNF-α TN3-19.12 X X
Mouse TNF-α MP6-XT22 X X X X X X X X
Mouse TRANCE IK22/5 X X X
Human
Human IL-1α 364-3B3-14 X X
Human IL-1β JK1B-1 X X
Human IL-2 MQ1-17H12 X X X X X X X
Human IL-3 BVD3-1F9 X X X
Human IL-4 8D4-8 X X
Human IL-4 MP4-25D2 X X X X X X X
Human IL-5 JES1-39D10 X X
Human IL-5 TRFK5 X X X
Human IL-6 MQ2-13A5 X X X X
BioLegend Cytokine and Chemokine Antibodies and Antibody Conjugates
Intracellular Cytokine Staining Resource GuideIntracellular Cytokine Staining Resource Guide
www,biolegend.com • [email protected] 15
Specificity Clone Puri
fied
Bio
tin
FITC
PE APC
Ale
xa F
luor
® 48
8
Ale
xa F
luor
® 64
7
Ale
xa F
luor
® 70
0
Human (continued)
Human IL-8 JK8-1 X X
Human IL-9 MH9A4 X X
Human IL-10 JES3-9D7 X X X X X X
Human IL-10 JES3-19F1 X X X
Human IL-12/IL-23 p40 C11.5 X X X X
Human IL-13 JES10-5A2 X X X
Human GM-CSF BVD2-21C11 X X X
Human IFN-γ 4S.B3 X X X X X X X X
Human IFN-γ B27 X X X X X
Human MCP-1 5D3-F7 X X X
Human MCP-1 2H5 X X
Human TNF-α MAb11 X X X X X X X X
Human TNF-β 359-81-11 X X X
Rat
Rat IFN-γ DB-1 X X X
Rat MCP-1 2H5 X X
Rat TNF-α TN3-19.12 X X
Related Products
Cell Staining Buffer (FBS) Cat. No. 420201
RBC Lysis Buffer (10X) Cat. No. 420301
Brefeldin A Solution (1,000X) Cat. No. 420601
Monensin Solution (1,000X) Cat. No. 420701
Fixation Buffer Cat. No. 420801
Permeabilization Wash Buffer (10X) Cat. No. 421001
BioLegend Cytokine and Chemokine Antibodies and Antibody Conjugates (continued)